Recursion Pharmaceuticals (RXRX) Q2 2024 earnings summary

Executive summary

• Announced a stock-for-stock business combination with Exscientia to create a leading technology-enabled drug discovery platform, expanding AI-driven capabilities and a diversified clinical pipeline.

• Combined entity will have approximately $850 million in cash as of Q2 2024, with annual synergies of $100 million or more and a cash runway into 2027.

• The transaction is expected to close by early 2025, pending shareholder and regulatory approvals.

• Strategic partnerships with Roche, Genentech, Bayer, Sanofi, Merck KGaA, and NVIDIA drive significant milestone opportunities and innovation, including a $30 million milestone from Roche-Genentech.

• Operationalized BioHive-2 supercomputer, ranked 35th globally, enhancing computational drug discovery.

Financial highlights

• Combined cash position at Q2 2024 was approximately $850 million, with operational runway into 2027 and anticipated annual savings of over $100 million from synergies.

• Q2 2024 revenue was $14.4 million, up 31% year-over-year, mainly from the Roche partnership.

• Net loss for Q2 2024 was $97.5 million, a 27% increase year-over-year; research and development expenses rose to $73.9 million.

• Accumulated deficit reached $1.2 billion as of June 30, 2024.

• No new share issuance planned for the merger; transaction structured as a share exchange.

Outlook and guidance

• Combined pipeline targets approximately 10 clinical and near-clinical readouts in the next 18 months, with most programs having $1 billion or more peak sales potential.

• Management expects the business combination to close by early 2025, subject to approvals.

• Cash runway projected to extend into 2027 post-combination.